Sign In
Buy NBIX
$175.77
+1.62 (+0.93%)
At Close: Jul 24, 2026
PDUFA Target Action Dates in Late December 2024 Highly Selective CRF1 Antagonist is the Potential First New Treatment for CAH in 70 Years SAN DIEGO , July 1, 2024 /PRNewswire/ -- Neurocrine Bioscienc
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
03:27pm, Monday, 17'th Jun 2024
Biotech stocks operate under a core ethos. While there's been much talk about financially viable sectors – from tech to cryptocurrencies to even precious metals – when you think about it, nothing
SAN DIEGO , June 3, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Diurnal Ltd., a Neurocrine Biosciences company, presented information from its neuroendocrinology pipeline at t
- CAHtalyst™ Pediatric Study Met Primary and Key Secondary Endpoints, with Crinecerfont Treatment Decreasing Androstenedione Levels and Enabling Glucocorticoid Dose Reduction While
- CAHtalyst™ Adult Phase 3 Study Met Primary and Important Key Secondary Endpoints, with Crinecerfont Treatment Decreasing Androstenedione Levels and Enabling Glucocorticoid Dose R
Neurocrine Biosciences to Participate at Investor Conferences in June
04:01pm, Wednesday, 29'th May 2024
Jefferies Global Healthcare Conference on June 5 in New York Goldman Sachs 45th Annual Global Healthcare Conference on June 13 in Miami SAN DIEGO, May 29, 2024 /PRNewswire/ -- Neurocrine Biosciences,
Neurocrine founder-CEO Gorman to retire in October
05:07pm, Tuesday, 28'th May 2024
Neurocrine Biosciences CEO Kevin Gorman will retire on Oct. 11 after three decades with the company that he founded and will be succeeded by insider Kyle Gano.
Neurocrine Biosciences Announces CEO Succession Plan
04:14pm, Tuesday, 28'th May 2024
Board of Directors appoints Kyle Gano, Ph.D., Chief Business Development and Strategy Officer, as CEO-elect, effective October 11, 2024 Kevin Gorman, Ph.D.
New CAHtalyst™ Pediatric and CAHtalyst™ Adult Phase 3 Clinical Study Data in Congenital Adrenal Hyperplasia CAHtalog™ Registry Data Highlighting Impact of Supraphysiologic Glucocorticoid Dosing
SAN DIEGO , May 21, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of data from a post hoc analysis of the Phase 3 KINECT®-4 study of INGREZZA® (va
- CAHtalyst™ Phase 3 Baseline Characteristics Highlight Limitations of Current CAH Treatment Paradigm in Children, Adolescents and Adults - Phase 2 Study for Modified-Release Hydrocortisone in Adult
CAHtalyst™ Study Baseline Characteristics Highlight the Need for New Treatment Options to Reduce Adrenal Androgens and Supraphysiologic Glucocorticoid Dosing in CAH Adult Patients Comprehensive Lite
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults
08:30am, Thursday, 09'th May 2024
SAN DIEGO , May 9, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the safety, tolerability, ph
Nxera Pharma's partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
02:35am, Thursday, 09'th May 2024
Tokyo, Japan and Cambridge, UK, 9 May 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) notes that its partner Neurocrine Biosciences Inc. (“Neurocrine”; Nasdaq: NBIX), a leading
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
08:30am, Wednesday, 08'th May 2024
SAN DIEGO , May 8, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the safety, tolerability, p
